NCT05690386 - A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

December 31, 2027

Conditions

Turner Syndrome

Interventions

BIOLOGICAL

Lonapegsomatropin

Once-weekly subcutaneous injection of Lonapegsomatropin

DRUG

Somatropin

Once-daily subcutaneous injection of Somatropin

Trial Locations (19)

11042

Ascendis Pharma Investigational Site, Lake Success

27599

Ascendis Pharma Investigational Site, Chapel Hill

30322

Ascendis Pharma Investigational Site, Atlanta

32827

Ascendis Pharma Investigational Site, Orlando

45229

Ascendis Pharma Investigational Site, Cincinnati

55102

Ascendis Pharma Investigational Site, Saint Paul

60611

Ascendis Pharma Investigational Site, Chicago

73104

Ascendis Pharma Investigational Site, Oklahoma City

76104

Ascendis Pharma Investigational Site, Fort Worth

79902

Ascendis Pharma Investigational Site, El Paso

80045

Ascendis Pharma Investigational Site, Aurora

83404

Ascendis Pharma Investigational Site, Idaho Falls

89113

Ascendis Pharma Investigational Site, Las Vegas

92123

Ascendis Pharma Investigational Site, San Diego

94304

Ascendis Pharma Investigational Site, Palo Alto

97239

Ascendis Pharma Investigational Site, Portland

98105

Ascendis Pharma Investigational Site, Seattle

33701-4804

Ascendis Pharma Investigational Site, St. Petersburg

02114

Ascendis Pharma Investigational Site, Boston

All Listed Sponsors

lead

Ascendis Pharma Endocrinology Division A/S

INDUSTRY